Latest Commercialisation News

TruScreen Group Limited has successfully raised NZ$2.35 million through a share placement, attracting new institutional investors from Asia, while launching a discounted share purchase plan for existing shareholders.

Delta Lithium Limited has announced a proposed demerger involving an in-specie distribution of over 63 million Ballard Mining shares to eligible shareholders, pending approval at a June 30 meeting. This move will reduce Delta's stake in Ballard and set the stage for Ballard's eventual ASX listing.

Papyrus Australia has secured a pivotal contract with UniSA to establish a Rapid Prototyping and R&D facility, advancing its sustainable packaging technology and commercial production plans.

Sparc Technologies has entered a strategic collaboration with Detmold Packaging to develop graphene-enhanced paper packaging products that promise improved durability and sustainability.

Nanollose Limited has appointed Andrew Moullin as its new CEO and Managing Director, aiming to leverage his extensive commercial expertise to fast-track the company’s microbial cellulose technology towards market readiness.

Equinox Resources has obtained a crucial exploration permit for its Alturas Antimony Project in British Columbia, paving the way for a comprehensive 2025 field program and potential bulk sampling. This milestone advances the company’s strategy amid rising North American demand for critical minerals.

The Arkansas Oil & Gas Commission has approved a 2.5% lithium royalty for brine projects, providing Pantera Lithium with regulatory clarity and a competitive fiscal framework that enhances its Smackover Project’s commercial prospects.

QEM Limited has raised A$2.05 million through a strongly supported placement to accelerate its Julia Creek Vanadium and Energy Project, coinciding with the retirement of founding CEO Gavin Loyden and the appointment of Robert Cooper as his successor.

Ionic Rare Earths has announced a $3 million capital raise via convertible notes, aimed at advancing its rare earth projects across multiple continents. The raise, pending shareholder approval, underscores the company’s strategic push into sustainable rare earth extraction and recycling technologies.

Clarity Pharmaceuticals has successfully imaged the first patient in its pivotal Phase III AMPLIFY trial for Cu-SAR-bisPSMA, a next-generation diagnostic agent targeting recurrent prostate cancer. This milestone sets the stage for potential FDA approval and broader clinical adoption.

Green360 Technologies has developed a proprietary low-carbon cement blend using red mud and kaolin, achieving significant reductions in hazardous leachates and competitive strength performance. The company is poised to begin commercial-scale validation with JV partner PERMAcast.

Avecho Biotechnology has received $1.66 million from the Australian Government’s R&D Tax Incentive, reinforcing its commitment to a pivotal Phase III trial for its CBD-based insomnia treatment and accelerating its commercial ambitions.